Skip to main content
Fig. 1 | Molecular Medicine

Fig. 1

From: Administration of zoledronic acid alleviates osteoporosis in HIV patients by suppressing osteoclastogenesis via regulating RANKL expression

Fig. 1

CTx and Osteocalcin expression was suppressed by ZOL treatment in HIV patients receiving tenofovir treatment. a Model-based mean longitudinal changes of CTx concentration in 48 weeks in ZOL-treated HIV patients receiving tenofovir treatment. b Model-based mean CTx percentage change from baseline in 48 weeks in ZOL-treated HIV patients receiving tenofovir treatment. c Model-based mean longitudinal changes of Osteocalcin concentration in 48 weeks in ZOL-treated HIV patients receiving tenofovir treatment. d Model-based mean Osteocalcin percentage change from baseline in 48 weeks in ZOL-treated HIV patients receiving tenofovir treatment

Back to article page

Molecular Medicine

ISSN: 1528-3658